# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 03-14-2024 | 12-31-2023 | 10-K | |
2 | 11-09-2023 | 09-30-2023 | 10-Q | |
3 | 08-03-2023 | 06-30-2023 | 10-Q | |
4 | 05-09-2023 | 03-31-2023 | 10-Q | |
5 | 03-15-2023 | 12-31-2022 | 10-K |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-SEC Filing
Maxim Group analyst Naz Rahman maintains Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy and lowers the price target from $15...
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(2.08) per share which beat the analyst consensus estimate of...
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday. The Dow traded do...